



Achillion Pharmaceuticals
Investor Relations Department
300 George St.
New Haven, CT 06511
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ACHN

Last Trade:	3.92
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	-0.08 ↓ (-2.000%)
Day Range	3.90 - 4.03
52-Week Range	2.58 - 5.66
Volume	4,148,014

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Mar 8, 2018*
[Achillion to Present at the Barclays Global Healthcare Conference](#)
- Feb 28, 2018*
[Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G™ Initiative as Part of Rare Disease Day 2018](#)
- Feb 26, 2018*
[Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy](#)
- Feb 22, 2018*
[Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results](#)
- Feb 9, 2018*
[Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference](#)

Financial Disclosures [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 22, 2018*
[Annual Report \(10-K\)](#)
- Apr 17, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)